Eight key areas to improve brain tumour diagnosis have been identified in Scotland following a roundtable discussion with healthcare experts.
The Brain Tumour Charity and Dxcover Ltd. facilitated a discussion with GPs, NHS representatives, researchers, the co-convenor of the Cross Party Group on Cancer and representatives from the Chief Scientist’s Office, to improve diagnosis for people with a suspected brain tumour.
Each year, more than 1000 people in Scotland are diagnosed with a brain or central nervous system tumour (1), leading to urgent calls to prioritise better care and improve pathways to a faster diagnosis.
Following the discussion with the panel of experts in February 2024 and further research, a report was produced in partnership with The Brain Tumour Charity and Dxcover which identified eight key areas as having the most potential for improving brain tumour diagnosis.
They include ensuring that patients are monitored throughout their diagnosis until symptoms are explained or resolved, enabling optometrists to refer directly to neurology if a person presents with concerning visual symptoms and prioritising innovation to improve diagnosis of brain tumour.
12 recommendations have now been made to NHS Scotland and the Scottish Government about the changes required to ensure diagnosis pathways are effective.
The recommendations include providing guidelines to improve care and raise awareness of brain tumours, allowing opticians to refer directly to neurology and establishing a diagnostic/triage tool that would help diagnose people faster (2).
The roundtable also started a discussion on where a diagnostic tool would be most suitable in healthcare pathways. Dxcover Ltd is a Glasgow based company developing diagnostic tools for brain tumours and has developed a liquid biopsy test with artificial intelligence that could be used in the brain tumour diagnosis pathway.
The Brain Tumour Charity and Dxcover will continue to work with NHS Scotland and the Scottish Government to ensure that people with a suspected brain tumour are prioritised and that the pathway to diagnosis is improved for patient benefit.
Cameron Miller, Director of External Affairs and Strategy at The Brain Tumour Charity said: “The recommendations we are suggesting to improve the brain tumour diagnosis pathway in Scotland are based on a fruitful and impactful discussion The Brain Tumour Charity and Dxcover initiated with Scottish healthcare professionals and policymakers.
“These are stepping stones to improving diagnosis for people living in Scotland and we are committed to ensuring that people facing a brain tumour diagnosis have the support they need to ensure they are diagnosed faster and have the quickest access to the best treatments available.”
Prof. Matthew J. Baker, CEO of Dxcover said: “Dxcover was founded to enable the earliest detection of cancer. We believe that the combination of Dxcover’s multi-omic spectral analysis and machine learning will lead to the greatest impact on patient recovery, lifespan and quality of life post-diagnosis.
“We have recently launched our EMBRACE study, a pan-Europe 2,200 patient performance evaluation of the Dxcover® Brain Cancer Liquid Biopsy which will enable CE marking and provide a much-needed tool for patients.”
24
0
20
